Lecanemab in Early Alzheimer's Disease.
Published in The New England journal of medicine • Jan 5, 2023
Authors:,,
Christopher H van Dyck
Chad J Swanson
Paul Aisen
Abstract
BACKGROUND: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early A...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!